CSF3 and Miyoshi myopathy: In 2008, it was approved by the US Food and Drug Administration (FDA) and combined with granulocyte colony stimulating factor (G-CSF) as a hematopoietic stem cell mobilization agent for autologous transplantation of patients with non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM) [49].